NRIX

Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Recently, Nurix secured a partnership with Roche, which I believe has substantially derisked the stock as a whole. Similarly, this deal helps validate NRIX's bexobrutideg and its potential as a broader platform in the long term. NRIX's bexobrutideg is easily their main value driver, and after NRIX's recent equity raises and deal with Roche, it looks like they should have enough runway for the foreseeable future.

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement Data to be presented at the 2026 European Hematology Association (EHA) Congress BRISBANE, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced updated clinical data from the Company's ongoing NX-5948-301 Phase 1a/b clinical trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic lymphocytic leukemia (CLL).

Nurix Therapeutics, Inc. remains a Strong Buy as bexobrutideg advances in pivotal r/r CLL trials and secures a transformative $2.3B global partnership with Roche. Bexobrutideg demonstrates superior efficacy over JAYPIRCA, achieving an 83% ORR and 22.1 months mPFS in heavily pretreated r/r CLL patients at the 600 mg dose. The Roche deal brings $700M upfront, potential total value of $2.3B in milestones, and enables expansion into immunology and neurology, notably multiple sclerosis and chronic spontaneous urticaria.

Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases Transcript

Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.